This page lists the surgical oncology hospitals in our directory offering Esophageal Cancer Treatment in Chennai, India, including Apollo Hospitals, Greams Road, Gleneagles Global Hospital, Dr. Rela Institute and Medical Centre, SIMS Hospital and others. Each listing links through to the hospital's full profile page.
Ask us about esophageal cancer treatment in Chennai, India
Share a few details and our care coordination team will get back to you with next steps.
Compare 8 accredited hospitals for Surgical Oncology in Chennai, India
🇮🇳 Apollo Hospitals, Greams Road
🇮🇳 Gleneagles Global Hospital
🇮🇳 Dr. Rela Institute and Medical Centre
🇮🇳 SIMS Hospital
🇮🇳 Sankara Nethralaya
🇮🇳 Apollo First Med Hospitals, Kilpauk
🇮🇳 MIOT International
🇮🇳 MGM Healthcare
How we selected these hospitals
A hospital appears on this page when Surgical Oncology is among its listed specialties and it is located in Chennai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Esophageal Cancer Treatment in Chennai, India?
Choosing the right hospital for esophageal cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include surgical oncology rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Esophageal Cancer Treatment
Esophageal cancer treatment encompasses a multimodal spectrum of interventions — including minimally invasive esophagectomy, chemoradiotherapy, targeted therapy, and immunotherapy — tailored to tumor histology, staging (TNM), and patient performance status. Centers of excellence in India and the UAE report 5-year survival rates of 40–60% for early-stage (Stage I–II) disease and 15–25% for locally advanced (Stage III) disease when treated with curative intent using current protocols. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology centers in India and JCI- and DHA-licensed hospitals in Dubai and Abu Dhabi, offering end-to-end coordination from diagnosis confirmation through post-treatment surveillance.
Clinical Overview
Esophageal cancer is a malignancy arising from the epithelial lining of the esophagus, with two dominant histological subtypes: squamous cell carcinoma (SCC), predominating in the upper and middle thirds and strongly associated with tobacco and alcohol use, and adenocarcinoma (EAC), arising predominantly at the gastroesophageal junction (GEJ) and strongly linked to Barrett's esophagus, chronic gastroesophageal reflux disease (GERD), and obesity. Globally, esophageal cancer ranks as the seventh most common cancer and the sixth leading cause of cancer-related mortality, with an estimated 600,000 new cases annually. The anatomical position of the esophagus — traversing the mediastinum and interfacing with the trachea, aorta, and thoracic duct — makes it a technically demanding site for both diagnosis and resection.
Full details →Who is a Candidate?
- ELIGIBLE PATIENTS — CURATIVE INTENT:
- Histologically confirmed esophageal SCC or adenocarcinoma (biopsy via upper GI endoscopy with EUS-guided sampling)
- Clinical staging T1b–T4a, N0–N3, M0 (resectable or borderline resectable disease per AJCC 8th Edition TNM staging)
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0–2
- Adequate cardiopulmonary reserve: FEV1 > 1.5 L (or >60% predicted), DLCO > 60%, LVEF ≥ 50% on echocardiography (ECHO)
- +20 more
Treatment Options & Approaches
ENDOSCOPIC RESECTION (Stage T1a/T1b, Early Disease):
- Endoscopic Mucosal Resection (EMR): Suitable for flat, superficial lesions confined to the mucosa (<2 cm). Uses submucosal injection and snare resection. Low morbidity, outpatient or short-stay procedure.
- Endoscopic Submucosal Dissection (ESD): Preferred for larger en bloc resection of T1a lesions. Provides superior R0 resection margins and intact specimen for histopathological assessment. Requires expert endoscopist; available at tertiary centers in Mumbai, Chennai, Delhi, Dubai, and Abu Dhabi.
- Radiofrequency Ablation (RFA): Used for Barrett's esophagus with high-grade dysplasia or residual flat Barrett's post-EMR, to reduce metachronous cancer risk.
SURGICAL RESECTION (Stage T1b–T3, Resectable T4a):
- Ivor Lewis Esophagectomy (transthoracic, two-field): Right thoracotomy + laparotomy with intrathoracic anastomosis. Gold-standard approach for mid-to-lower esophageal and GEJ tumors. Allows two-field lymphadenectomy (mediastinal + abdominal).
- McKeown Esophagectomy (three-stage, three-field): Right thoracotomy + laparotomy + left neck incision with cervical anastomosis. Preferred for upper and mid-esophageal SCC with cervical lymph node involvement. Allows three-field lymphadenectomy.
- Transhiatal Esophagectomy (THE): Laparotomy + left neck incision without thoracotomy. Lower pulmonary morbidity; suitable for high-risk pulmonary patients, but limited mediastinal visualization.
- Minimally Invasive Esophagectomy (MIE — Thoracoscopic + Laparoscopic): Now the preferred approach at high-volume centers. Meta-analyses confirm significantly reduced pulmonary complications, shorter ICU stay, and equivalent oncological outcomes versus open surgery. Requires laparoscopic gastric conduit formation and thoracoscopic esophageal mobilization.
- Robotic-Assisted Minimally Invasive Esophagectomy (RAMIE): Performed with the da Vinci Surgical System (Xi platform). Offers 3D magnification, articulated instrumentation, and tremor filtration — particularly advantageous for precise lymphadenectomy in the paratracheal and subcarinal nodes. Available at AIIMS New Delhi, Tata Memorial Mumbai, Apollo Hospitals, Medanta, Cleveland Clinic Abu Dhabi, and Mediclinic City Hospital Dubai. Studies (TIME trial, ROBOT trial) confirm non-inferior oncological safety and superior short-term surgical outcomes versus open esophagectomy.
- Gastric Conduit Reconstruction: Standard conduit for esophageal replacement. Colonic or jejunal interposition used when stomach is unavailable (e.g., prior gastric surgery).
Recovery
PHASE 1 — PRE-TRAVEL & REMOTE CONSULTATION (Weeks 1–2):
- Patient submits medical records (endoscopy report, biopsy histology, CT/PET-CT, PFTs, ECHO, blood work) to GAF Healthcare's medical team.
- GAF coordinates a teleconsultation with the treating oncologist and thoracic surgeon at the selected center within 48–72 hours.
- Tumor board (MDT) review completed remotely; treatment plan (surgical vs. chemoradiotherapy vs. multimodal) communicated to patient.
- Cost estimate, visa invitation letter, and logistics plan issued by GAF Healthcare coordinator.
PHASE 2 — ARRIVAL & STAGING CONFIRMATION (Days 1–4 in country):
Full details →Risks to be aware of
Esophageal cancer treatment carries procedure-specific and cumulative risks that patients must understand before undertaking treatment abroad. The most serious surgical complication is anastomotic leak — an incomplete seal at the esophageal-gastric conduit junction — occurring in 5–15% of cases, which may require endoscopic stenting, drainage, or re-intervention and can extend hospitalization by 1–3 weeks. Pulmonary complications (pneumonia, atelectasis, acute respiratory distress syndrome) affect 15–30% of patients post-esophagectomy and represent the leading cause of 30-day post-operative mortality (overall 30-day mortality at high-volume centers: 1–3%). Chylothorax (thoracic duct injury causing lymphatic leak into the pleural cavity) occurs in 2–4% of cases and may require re-operation or pleurodesis. Recurrent laryngeal nerve injury — resulting in vocal cord paresis and hoarseness — occurs in 5–10% of three-stage procedures; most resolve within 3–6 months. Delayed gastric conduit emptying (conduit dysmotility) affects up to 20% of patients and is managed with prokinetics and dietary modification. Chemoradiotherapy carries its own toxicity profile: myelosuppression (nadir at Day 10–14 of each cycle requiring G-CSF support), radiation esophagitis (Grade 2–3 in up to 40% of patients), nephrotoxicity (cisplatin-based regimens), peripheral neuropathy (paclitaxel/oxaliplatin), and immune-related adverse events (irAEs) with PD-1 inhibitors (colitis, pneumonitis, hepatitis — managed with corticosteroid protocols). Nutritional deterioration is a cross-cutting risk: pre-operative malnutrition increases post-operative complication rates by 2–3 fold; all patients should have formal nutritional assessment and optimization prior to surgery. Long-term, patients must adapt to structural changes: smaller stomach capacity (conduit volume ~300–400 mL), altered gastric motility, increased aspiration risk, dumping syndrome (early satiety, vasomotor symptoms post-meals), and bile reflux. Patients traveling internationally for treatment must also account for the risk of delayed access to emergency care during the post-operative period — a primary reason GAF Healthcare mandates a minimum 6-week in-country post-esophagectomy stay before fit-to-fly clearance.
Why GAF Healthcare
GAF Healthcare provides comprehensive end-to-end non-medical coordination for international patients undergoing esophageal cancer treatment in India and the UAE.
Common questions about Esophageal Cancer Treatment
What is the cost of Esophageal Cancer Treatment in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after esophageal cancer treatment?
What is the success rate of Esophageal Cancer Treatment?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Esophageal Cancer Treatment in Chennai, India
Discover the Top Hospitals for Esophageal Cancer Treatment in Chennai, India
This page lists 8 accredited surgical oncology hospitals in Chennai, India, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about esophageal cancer treatment in Chennai, India
How many surgical oncology hospitals are listed in Chennai, India?
How do you choose which hospitals to list?
How much does treatment cost in India?
Are there surgical oncology hospitals for this in other India cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for esophageal cancer treatment in Chennai, India.
Contact us to report an inaccuracy on this page.